rs114633080 - UTRN - EPM2A

Magnitude 2.0 · 1 study on file

Reported associations

• No genetic association detected with mepolizumab efficacy in severe asthma. - Respiratory medicine (2018) · Condreay L, Chiano M, Ortega H, Buchan N, Harris E, Bleecker ER, Thompson PJ, Humbert M, Gibson P, Yancey S, Ghosh S · PubMed 29229094

  Treatment with mepolizumab, a humanized monoclonal antibody to interleukin-5, reduces the rate of asthma exacerbations and the requirement for systemic glucocorticoids while maintaining asthma control. Treatment decisions are guided by predictors of response, including blood eosinophil thresholds in patients with frequent exacerbations despite intensive anti-inflammatory and controller treatment. Identification of additional predictors of response could aid treatment decisions. We investigated genetic associations that may predict response to mepolizumab-treatment. In this post hoc analysis of DREAM and MENSA, association of genetic markers was tested in patients with severe asthma treated with mepolizumab who provided consent for pharmacogenetic research. Association was tested in a tiere

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.